Patient characteristics by post–cycle 2 result
| Characteristic . | N (%) . | P† . | |
|---|---|---|---|
| PET−* (n = 135) . | PET+* (n = 14) . | ||
| Age, y | .16 | ||
| Median | 31 | 30 | |
| Range | 19-58 | 18-46 | |
| Race | .12 | ||
| White | 116 (86) | 10 (71) | |
| Black or African American | 9 (7) | 1 (7) | |
| Asian | 4 (3) | 0 | |
| Not reported/unknown | 6 (4) | 3 (21) | |
| Ethnicity | .50 | ||
| Hispanic or Latino | 6 (4) | 1 (7) | |
| Non-Hispanic | 121 (90) | 12 (86) | |
| Not reported/unknown | 8 (6) | 1 (7) | |
| Sex | .85 | ||
| Male | 71 (53) | 7 (50) | |
| Female | 64 (47) | 7 (50) | |
| Stage | .46‡ | ||
| IA | 15 (11) | 1 (7) | |
| IB | 2 (1) | 1 (7) | |
| IIA | 81 (60) | 7 (50) | |
| IIB | 30 (22) | 5 (36) | |
| IIAE | 2 (1) | 0 | |
| IIBE | 2 (1) | 0 | |
| Not reported/unknown | 3 (2) | 0 | |
| Performance score | .09 | ||
| ECOG/Zubrod = 0 | 104 (77) | 8 (57) | |
| ECOG/Zubrod = 1 | 28 (21) | 6 (43) | |
| Not reported/unknown | 3 (2) | 0 | |
| ESR | .35 | ||
| <50 | 93 (69) | 8 (57) | |
| 50+ | 34 (25) | 5 (36) | |
| Not reported/unknown | 8 (6) | 1 (7) | |
| GHSG | .16 | ||
| Favorable | 57 (42) | 3 (21) | |
| Unfavorable | 78 (58) | 11 (79) | |
| EORTC/LYSA/FIL | .57 | ||
| Favorable | 81 (60) | 7 (50) | |
| Unfavorable | 54 (40) | 7 (50) | |
| Characteristic . | N (%) . | P† . | |
|---|---|---|---|
| PET−* (n = 135) . | PET+* (n = 14) . | ||
| Age, y | .16 | ||
| Median | 31 | 30 | |
| Range | 19-58 | 18-46 | |
| Race | .12 | ||
| White | 116 (86) | 10 (71) | |
| Black or African American | 9 (7) | 1 (7) | |
| Asian | 4 (3) | 0 | |
| Not reported/unknown | 6 (4) | 3 (21) | |
| Ethnicity | .50 | ||
| Hispanic or Latino | 6 (4) | 1 (7) | |
| Non-Hispanic | 121 (90) | 12 (86) | |
| Not reported/unknown | 8 (6) | 1 (7) | |
| Sex | .85 | ||
| Male | 71 (53) | 7 (50) | |
| Female | 64 (47) | 7 (50) | |
| Stage | .46‡ | ||
| IA | 15 (11) | 1 (7) | |
| IB | 2 (1) | 1 (7) | |
| IIA | 81 (60) | 7 (50) | |
| IIB | 30 (22) | 5 (36) | |
| IIAE | 2 (1) | 0 | |
| IIBE | 2 (1) | 0 | |
| Not reported/unknown | 3 (2) | 0 | |
| Performance score | .09 | ||
| ECOG/Zubrod = 0 | 104 (77) | 8 (57) | |
| ECOG/Zubrod = 1 | 28 (21) | 6 (43) | |
| Not reported/unknown | 3 (2) | 0 | |
| ESR | .35 | ||
| <50 | 93 (69) | 8 (57) | |
| 50+ | 34 (25) | 5 (36) | |
| Not reported/unknown | 8 (6) | 1 (7) | |
| GHSG | .16 | ||
| Favorable | 57 (42) | 3 (21) | |
| Unfavorable | 78 (58) | 11 (79) | |
| EORTC/LYSA/FIL | .57 | ||
| Favorable | 81 (60) | 7 (50) | |
| Unfavorable | 54 (40) | 7 (50) | |
ECOG, Eastern Cooperative Oncology Group; EORTC, European Organisation for Research and Treatment of Cancer; ESR, erythrocyte sedimentation rate; FIL, Fondazione Italiana Linfomi; GHSG, German Hodgkin Study Group; LYSA, Lymphoma Study Association.
Patients withdrawn/cancelled/not eligible before interim PET were excluded; refer to Figure 1 (CONSORT diagram).
Statistical tests: Kruskal-Wallis test for comparing medians; χ2 test for comparing categorical characteristics by interim PET result; Fisher’s exact test when χ2 assumptions not satisfied; missing data not included in comparisons.
A vs B P = .21.